VACV Specific Neutra™ Antibody Products

Vaccinia virus (VACV), belonging to the Poxviridae family, stands as a structurally intricate DNA pathogen. This large virus served as the fundamental biological tool enabling smallpox eradication through immunization programs. Although capable of inducing localized cutaneous infections (vaccinia) in humans, VACV differs from variola virus, the causative agent of smallpox. The immunological cross-reactivity between these orthopoxviruses allowed VACV-based vaccines to generate protective immunity against smallpox. The virus demonstrates broad zoonotic potential, infecting diverse mammalian and avian species. Primary transmission occurs through contact with infectious dermal lesions or contaminated surfaces, with some evidence suggesting occasional aerosol transmission under specific circumstances.

VACV Genome Structure

VACV possesses an unusually large linear double-stranded DNA genome measuring approximately 190 kb pairs. This extensive genetic complement encodes nearly 250 viral genes that support autonomous cytoplasmic replication, minimizing reliance on host nuclear processes. The genomic architecture features inverted terminal repeats (ITRs) at both termini, a distinctive attribute facilitating genome circularization during replication cycles. These palindromic sequences also participate in DNA repair mechanisms. Gene organization demonstrates high density with bidirectional transcription capacity, allowing simultaneous expression from complementary DNA strands.

Fig. 1 The VACV genome.¹

VACV Virion Structure

The vaccinia virion is a large, pleomorphic, enveloped particle, brick-shaped or ovoid, typically measuring 250 × 350 nm with particle masses ranging 5-10 fg. The intricate architecture comprises multiple concentric membranes surrounding a DNA-packed core containing essential replication enzymes. Two principal infectious forms exist: intracellular mature virions (IMVs) bounded by a single membrane layer, and extracellular enveloped virions (EVs) acquiring additional host-derived outer membranes. These structural variations mediate distinct infection phases - IMVs facilitate cell-to-cell spread while EVs promote systemic dissemination. The layered membrane configuration provides robust environmental protection while enabling targeted host cell penetration.

Replication Cycle of VACV

• Entry: The entry of VACV starts with the binding of either an IMV or EEV to the cell surface. The virus attaches to the cell surface, and its outer membrane fuses with the host cell membrane, releasing the viral core into the cytoplasm. Entry can involve specific cell surface receptors and membrane fusion proteins.
• Transcription: Viral gene expression occurs in a temporally regulated manner. Early genes are transcribed first by viral RNA polymerase and encode proteins that modulate host defenses and are required for DNA replication.
• DNA Replication: VACV initiates genomic replication following early-stage protein expression. This process occurs within specialized cytoplasmic compartments and involves several viral enzymes, including its own DNA polymerase. The ITRs mediate replication initiation through complex nucleic acid interactions.
• Assembly: Late gene expression follows DNA replication and leads to the production of structural proteins and enzymes needed for virion assembly. New virions are assembled in the cytoplasm. IMVs are formed first, and some of these mature into EVs by acquiring additional membranes. Finally, the mature virions are released from the infected cell, either by cell lysis or through budding.

Fig. 2 The VACV life cycle.¹

Multiplicity Reactivation of VACV

VACV exhibits a phenomenon known as multiplicity reactivation (MR). MR is a process where two or more viral genomes, each with otherwise deadly damage (e.g., from UV irradiation), interact within the same infected cell to create live offspring viruses. In essence, the functional regions of one damaged genome can "rescue" the defective regions of another. This process highlights the robust DNA repair mechanisms of VACV and contributes to its genetic stability.

Antibodies Targeting VACV

Antibody-mediated immunity constitutes a central defense mechanism against VACV infection. Neutralizing antibodies achieve viral inhibition by binding surface epitopes, thereby obstructing cellular entry processes. Multiple virion surface proteins have been characterized as principal antibody targets. L1 emerges as a dominant neutralization antigen, while A27 contributes significantly to immune recognition of mature virions. The B5 glycoprotein, expressed exclusively on extracellular enveloped virions (EVs), represents another critical target with demonstrated importance in EV neutralization. Additional surface antigens, including D8 and H3, also induce protective antibody responses.

Experimental evidence confirms the potent neutralizing capacity of anti-L1 antibodies through epitope mapping studies. Another investigation has established anti-D8 antibodies' ability to interfere with viral adhesion mechanisms. These collective findings highlight the diagnostic and therapeutic value of antibodies targeting VACV surface antigens.

Creative Biolabs offers anti-VACV neutralizing antibody products, providing researchers with powerful tools for applications such as ELISA and neutralization assays. These products deliver accurate, reliable results, aiding in vaccine development, and advancing therapeutic antibody discovery.

REFERENCE

1. Al Ali, Sally, et al. "Use of reporter genes in the generation of vaccinia virus-derived vectors." Viruses 8.5 (2016): 134. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/v8050134